Table 1.
Analytical spectrum of molecular near-patient and point-of-care testing for infectious diseases
| System | Multiplexity | Virology | Microbiology |
|---|---|---|---|
|
ID NOW™ Abbott |
Single |
FLU A/B, RSV, SARS-CoV-2a |
GAS |
|
cobas® Liat® Roche |
Single | FLU A/B | GAS, CDI |
| Multiple | FLU A/B + RSV | ||
|
GeneXpert Omni Cepheid |
Single | EBO, EV, FLU A/B, HPV, HBV, HCV, HIV, SARS-CoV-2* |
GAS, TV, CT, GBS, CDI, CARBA-R, MRSA, NORO, VRE |
| Multiple | FLU A/B + RSV |
MTB + RIF, CT + NG, MRSA + SA |
|
|
binx io binx health, inc |
Single |
HPV, HIV, HCV, HBV, HSV-2 |
CT, NG, TV, TP, MG |
| Multiple |
CT + NG, CT + NG + TV, CT + NG + TV + MG |
||
|
FilmArrayb BioMerieux |
Multiple | Respiratory Panel: 18 viruses, 4 bacteria | |
|
Blood Culture Identification 2 (BCID2) Panel: 26 bacteria, 7 yeast, 10 antibiotic resistance genes | |||
| Gastrointestinal (GI) Panel: 5 viruses, 7 bacteria, 6 Diarrheagenic E. coli/Shigella, 4 parasites | |||
|
Meningitis-Encephalitis (ME) Panel: 7 viruses, 6 bacteria, 1 yeast | |||
|
Pneumonia plus Panel: 18 bacteria, 7 antibiotic resistance genes, 9 viruses | |||
| Verigeneb Nanosphere | Single | CDI | |
| Multiple |
Enteric Pathogens Test: 2 viruses, 6 bacteria, 2 toxins |
||
|
Respiratory Pathogens Flex test: 13 viruses, 2 bacteria | |||
|
Blood Culture Nucleic Acid Testing Panels: 1. Gram-positive: 8 species, 1 group, 4 genus, 3 resistance markers 2. Gram-negative: 5 species, 4 genus, 6 resistance markers | |||
|
GenePOC Meridian Bioscience, inc |
Single | CDI, GBS | |
|
Q-POC QuantuMDx |
Single | HPV, MDR-TB | |
| Multiple | CT + NG | ||
|
QIAstat-Dx Qiagen |
Multiple |
Respiratory Panel: 18 viral, 3 bacterial pathogens |
|
|
Respiratory SARS-CoV-2 panel*: 19 viral pathogens including SARS-CoV-2, 3 bacterial pathogens | |||
| Gastrointestinal Panel: 6 viral, 14 bacterial, 4 parasitic pathogens | |||
|
T2MR® T2 Biosystems |
Single | Candida | |
| Multiple | ESKAPE | ||
FLU A/B Influenza A/B, RSV respiratory syncytial virus, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, GAS group A streptococci, CDI Clostridium difficile, EBO Ebola virus, EV enterovirus, HPV human papillomavirus, HBV Hepatitis B virus, HCV Hepatitis C virus, HIV Human immunodeficiency virus, TV Trichomonas vaginalis, CT Chlamydia trachomatis, GBS group B streptococci, CARBA-R carbapenem-resistant Enterobacteriaceae, MRSA methicillin-resistant Staphylococcus aureous, NORO Norovirus, VRE Vancomycin-resistant enterococci, MTB Mycobacterium tuberculosis, RIF Rifampicin resistance, NG Neisseria gonorrhoeae, SA Staphylococcus, HSV-2 Herpes simplex virus type two, TP Treponema pallidum, MG Mycoplasma genitalium, MDR-TB Multi-drug resistance tuberculosis, ESKAPE Enterococcus faecium/Staphylococcus aureus/Klebsiella pneumoniae/Pseudomonas aeruginosa/Escherichia coli
aFor use under an Emergency-Use Authorization (EUA, 2020.09.24)
bNot POC